Table 1 Recently completed and currently ongoing clinical trials targeting DNA-PKcs
Inhibitor | Mode of Inhibition | Additional interventions | Phase | Location | Status/Trial |
|---|---|---|---|---|---|
Peposertib (M3814, MSC2490484A, Nedisertib) | selective SMI | Radium-223 dichloride, Avelumab | I/II | advanced castrate-resistant prostate cancer | Active NCT04071236 |
PLD | I/Ib | recurrent low or high grade ovarian cancer | Recruiting NCT04092270 | ||
MEC | I | relapsed or refractory acute myeloid leukemia | Recruiting NCT03983824 | ||
Tuvusertib (M1774) | I | advanced solid tumors | Recruiting NCT05687136 | ||
Lutetium 177 Dotatate | Ib | neuroendocrine tumors | Recruiting NCT04750954 | ||
radiation | I | Advanced head and neck cancer, cannot take cisplatin | Recruiting NCT04533750 | ||
Radiation, temozolomide | I | newly diagnosed MGMT unmethylated glioblastoma or gliosarcoma | Recruiting NCT04555577 | ||
Avelumab, radiation | II | advanced solid tumors | Completed (8-17-2022) NCT03724890 | ||
CC-115 | dual inhibitor of mTOR and DNA-PK | Monotherapy | II | Glioblastoma | Terminated NCT02977780 |
Enzalutamide (Enza) | I | castration-resistant prostate cancer (CRPC) | Completed (1-13-2023) NCT02833883 | ||
AZD7648 | selective SMI | PLD | I/IIa | advanced solid tumors | Completed (12-07-2022) NCT03907969 |
XRD-0394 | SMI, dual inhibitor of ATM and DNA-PK | Radiation | I | metastatic, locally advanced, or recurrent cancer | Active NCT05002140 |
AsiDNA | Sequesters DNA-PKcs and other DNA repair proteins | olaparib | Ib/II | recurrent solid tumors | Recruiting NCT05700669 |
Niraparib, Olaparib, Rucaparib | I/II | Relapsed Platinum Sensitive Ovarian Cancer | Recruiting NCT04826198 | ||
monotherapy | I | Advanced solid tumors | Completed 2-20-2022 NCT03579628 |
